Monitor upcoming clinical trial milestones for rezpegaldesleukin, particularly Phase 3 initiation timelines, as successful development could validate the capital raise and drive further upside. The strong cash position reduces near-term funding risk.
Price Chart
Executive Summary
Nektar Therapeutics is raising approximately $305.1 million through a public offering of 3.53 million common shares at $92.00 per share, with proceeds intended to fund clinical development of its lead drug candidates, including rezpegaldesleukin for autoimmune diseases and NKTR-255 for oncology. The offering follows positive Phase 2b data for rezpegaldesleukin in alopecia areata.
Key Facts
- Offering 3,532,609 shares of common stock at $92.00 per share, raising gross proceeds of $325 million
- Net proceeds estimated at $305.1 million after underwriting discounts and commissions
- Proceeds to be used for clinical development, including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata
- Recent positive Phase 2b data showed improved hair regrowth in alopecia areata patients with favorable safety profile
- Company had approximately $741.7 million in cash and marketable securities as of April 1, 2026
Financial Impact
Raises $305.1 million in net proceeds, increasing cash position by approximately 41% based on current cash balance
Risk Factors
- Dilution to existing shareholders - new investors experience $63.78 per share dilution
- Clinical development risk - drug candidates may fail in later-stage trials
- Market volatility - biotech stocks are particularly sensitive to clinical trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-171717 |
| Document: d138057dexfilingfees.htm | 0001193125-26-171717 |
| Document: 0001193125-26-171717-index-headers.html | 0001193125-26-171717 |
| Document: 0001193125-26-171717-index.html | 0001193125-26-171717 |
| Document: 0001193125-26-171717.txt | 0001193125-26-171717 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 9w ago | Press Release | $73.02 $68.50 | ▼ −6.19% | ▼ −4.20% | $35.78 (−51.00%) |
Aug 9, 2026 10w ago | Institutional Cluster | $74.86 $75.44 | ▲ +0.77% | ▲ +1.69% | $35.78 (−52.20%) |
Aug 7, 2026 10w ago | Court Ruling | $76.48 $74.19 | ▼ −2.99% | ▼ −2.60% | $35.78 (−53.22%) |
Jul 28, 2026 11w ago | Press Release | $70.68 $73.77 | ▲ +4.37% | ▼ −0.65% | $35.78 (−49.38%) |
Jun 11, 2026 18w ago | Institutional Cluster | $59.21 $72.92 | ▲ +23.15% | ▲ +21.26% | $35.78 (−39.57%) |
Jun 11, 2026 18w ago | Institutional Cluster | $59.21 $72.92 | ▲ +23.15% | ▲ +21.26% | $35.78 (−39.57%) |
May 21, 2026 21w ago | Insider Cluster | $66.61 $65.25 | ▲ +2.04% | ▲ +0.63% | $35.78 (+46.28%) |
May 8, 2026 23w ago | 8-K | $78.72 $56.23 | ▲ +28.57% | ▲ +28.27% | $35.78 (+54.55%) |
May 7, 2026 23w ago | 8-K | $81.89 $57.32 | ▼ −30.00% | ▼ −30.03% | $35.78 (−56.31%) |
Apr 24, 2026 25w ago | DEFA14A | $86.74 $65.56 | ▼ −24.42% | ▼ −29.37% | $35.78 (−58.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access